Abstract
Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.
Keywords: Atherosclerosis, high-density lipoproteins, lipids, risk factors.
Current Vascular Pharmacology
Title:Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
Volume: 12 Issue: 4
Author(s): Stephen J. Nicholls, Jordan Andrews and MyNgan Duong
Affiliation:
Keywords: Atherosclerosis, high-density lipoproteins, lipids, risk factors.
Abstract: Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.
Export Options
About this article
Cite this article as:
Nicholls J. Stephen, Andrews Jordan and Duong MyNgan, Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/1570161112999140411131155
DOI https://dx.doi.org/10.2174/1570161112999140411131155 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biogenic Peptides and Their Potential Use
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Limitations and Potential Clinical Application on Contrast Echocardiography
Current Cardiology Reviews Aging and DNA Methylation
Current Chemical Biology Intrinsically Fluorescent Base-Discriminating Nucleoside Analogs
Mini-Reviews in Organic Chemistry Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Epoxide Hydrolases and their Application in Organic Synthesis
Current Organic Chemistry Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Platelet Oxidative Stress and its Relationship with Cardiovascular Diseases in Type 2 Diabetes Mellitus Patients
Current Medicinal Chemistry Lipid Lowering Drugs and Gallstones: A Therapeutic Option?
Current Pharmaceutical Design Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention (Discontinued) Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants
Current Pharmaceutical Design Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Statins: A Valuable Tool for the Prevention/Regression of Abdominal Aortic Aneurysms
Vascular Disease Prevention (Discontinued) Antioxidant Properties and Associated Mechanisms of Salicylates
Current Medicinal Chemistry Editorial (Thematic Issue: Alcoholic Liver Disease: From Bench to Bedside)
Reviews on Recent Clinical Trials Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design